Examining and classifying reasons for missing viral loads among adults living with HIV: An extended outcome investigation and ascertainment approach in Western Kenya.

Harriet Fridah Adhiambo^{1,3}, Jayne Lewis-Kulzer², Edwin Nyagesoa¹, Sarah Gimbel³, Eliud Akama^{1,7}, Dorothy Mangale^{4,6}, Lina Montonya⁹, Ingrid Eshun-Wilson⁴, Sarah Iguna¹, Everlyne Nyandieka¹, Elizabeth Bukusi¹, Lisa Abuogi⁵, Thomas Odeny^{1,6}, Maya L. Petersen⁸, Elvin H. Geng⁴

- 1. Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
- Department of Obstetrics, Gynecology, and Reproductive Services, University of California, San Francisco, CA, USA
- 3. Department of Child, Family and Population Health Nursing, School of Nursing, University of Washington, Seattle, WA, USA
- Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis, MO, USA
- 5. Department of Pediatrics, University of Colorado, USA
- Division of Oncology, Department of Medicine, Washington University in St. Louis, MO, USA
- 7. Department of Global Health, University of Washington, Seattle, WA, USA
- Divisions of Biostatistics and Epidemiology, School of Public Health, University of California Berkeley, Berkeley, U.S.A.
- 9. Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA.

[§] Corresponding author: Harriet Fridah Adhiambo

4200 Mary Gates Memorial Drive NE Seattle, 98105, Washington, USA Phone number: +12065325701/+254726137703 Email: fridahadhiambo@gmail.com/ hfridah@uw.edu

It is made available under a CC-BY 4.0 International license .

E-mail addresses of authors:

JK: jayne.lewis.kulzer@gmail.com

- EN: nyagesoaedwin@gmail.com
- SG: <u>sgimbel@uw.edu</u>
- EA: eluakama@gmail.com
- DM: d.mangale@wustl.edu
- LM: <u>lmontoya@unc.edu</u>
- IW: wilson.ingrid@gmail.com
- SI: <u>sarah.iguna@gmail.com</u>
- EN: everlynenyandieka@gmail.com
- EB: ebukusi@rctp.or.ke
- LA: Lisa.Abuogi@childrenscolorado.org
- TA: <u>odeny@wustl.edu</u>
- MP: mayaliv@berkeley.edu
- EG: elvin.geng@wustl.edu

Keywords: Viral load, monitoring, HIV, Africa, and treatment

Word count: Abstract: 300/300 Main text: 3490

It is made available under a CC-BY 4.0 International license .

1 Abstract

Introduction: Gaps in HIV RNA monitoring persist globally impeding the ability to determine
clinical progress and outcomes. This study systematically evaluated provider (e.g., guideline nonadherence), system (e.g., laboratory error) and patient-based (e.g., refusal) drivers of missed viral
load (VL) monitoring measurements among adults living with HIV in Kenya.

Methods: Adults aged 18-65 years were followed across five health facilities in Kenya as part of
a clinical trial (NCT#02338739) where HIV RNA monitoring was done routinely. Instances of
missed VL despite being indicated per Kenyan guidelines were identified. An algorithm for
assessing root causes of missing HIV RNA was developed and generalized linear models estimated
the risk ratios (RR) for patient-level characteristics associated with missed viral load.

11

Results: Among 1,754 patients (66% female), the prevalence of missed viral load in year one and 12 two was 24.4% and 29.4%, respectively. Drivers for missed viral load measurements included loss 13 to follow up (51.5% in year one and 57.8% in year two), clinician non-adherence with guidelines 14 15 (36.7% in year one and 32.2% in year two), unknown (10.3% in year one and 8.6% in year two), 16 and requested but not collected (1.5% in year one and 1.3% in year two). Patients aged < 24 years (RR 2.27, 95% CI: 1.66-3.12), those with higher socioeconomic status (RR 1.47, 95% CI: 1.03-17 18 1.91), receiving HIV treatment at a rural clinic (RR 1.22, 95% CI: 1.02-1.46) and with advanced 19 HIV disease (RR 2.39, 95% CI: 1.52-3.73) were more likely to miss VL monitoring.

Conclusions: Missed routine viral load monitoring remains high, primarily due to loss to followup, and may substantially alter suppression estimates. Sustainable approaches to keep people living with HIV engaged in care, alongside strengthening providers' clinical practices and alignment with national guidelines, are necessary for optimizing viral monitoring and accurately assessing viral suppression within public health systems.

It is made available under a CC-BY 4.0 International license .

26 Introduction

The HIV response has greatly reduced mortality globally and in sub-Saharan Africa, including 27 28 Kenya [1]. The introduction of routine viral load monitoring for people on treatment for HIV in 29 Kenya was anticipated to be a gamechanger in 2013 [2]. Universal access to viral load allows clinicians to monitor patient health more effectively - detecting treatment failure earlier than 30 31 laboratory measures such as CD4 cell counts or clinical symptoms such as opportunistic 32 infections, resulting in improved management and decreased morbidity and mortality [3]. 33 Previously viral load measurements were reserved for complex patient cases or suspected viral 34 cases among extremely ill patients, with routine care measures relying on clinical or immunological indicators [3], [4]. 35 Despite the importance of routine viral load monitoring, gaps in HIV RNA monitoring persist, 36 impeding clinician ability to determine and shape patients' clinical progress and outcomes. 37 Existing data suggest that missed opportunities for viral load monitoring stem from a variety of 38 39 complex and multilevel health system barriers including reagent stock outs, staff shortages, poor 40 equipment maintenance and delayed clinical review and action on viral load results all of which impede progress toward epidemic control [5], [6]. An inefficient viral load monitoring system 41 not only compromises a clinician's ability to accurately detect treatment failure, but also delays 42 provision of timely treatment interventions to patients experiencing virologic failure, leading to 43 increased morbidity (including drug resistance), risk of HIV transmission as well as risk of 44 mortality [7], [8]. Additionally, there is a risk of missing broader trends and accurately 45 46 measuring viral suppression within the population.

47 Research has focused on associated factors of virologic failure, viral load uptake and monitoring,
48 and cost effectiveness of routine viral load monitoring [9], [10], [11], [12], [13]. The WHO

49	recommends routine viral load testing at 6 and 12 months post ART initiation and every 12
50	months thereafter [14]. In Kenya, although routine viral load monitoring has improved since its
51	introduction, patient follow up and data management systems at the facility level are known
52	barriers to the viral load monitoring process [15]. However, there is limited data examining the
53	degree of drivers of missing viral load among people with HIV [8]. To better discern issues
54	contributing to these gaps, we developed an algorithm to assess the root causes of missing HIV
55	RNA among adult patients with HIV on antiretroviral therapy (ART) and examined patient
56	characteristics and processes associated with timely viral load monitoring.
57	
58	Mathada
59	Methods Star las Daviers
60	Study Design
61	This cohort study was nested within a larger sequential multiple assignment trial (SMART),
62	AdaPT-R (NCT#02338739) study in Kenya. In the larger trial, HIV RNA monitoring during the
63	study was conducted entirely through routine service delivery processes at public health facilities
64	(i.e., the research staff did not ensure monitoring) and were thus representative of wider health
65	systems practice.
66	Study setting
67	The AdaPT-R study was conducted in the Nyanza region of western Kenya from September
68	2014 to December 2019 at five health facilities, including four government hospitals and one
69	faith-based health center [16]. Three sites were in urban Kisumu County: Lumumba Sub County
70	

It is made available under a CC-BY 4.0 International license .

- 71 more rural areas including Migori County: Rongo Sub County Hospital and Migori County
- 72 Referral Hospital. Both counties have a high HIV prevalence, 19.3% in Kisumu and 13.3% in
- 73 Migori, compared to the national prevalence of 4.9% [17], [18], [19].

74 Study population

- The study population included people living with HIV (PWH), \geq 18 years of age who had
- region for the remain in the Nyanza region for the
- duration of the study, had cell phone access and ability to read or be read short messages (SMS)
- messages, and were willing to be contacted by a clinic worker upon missing a clinic
- appointment. Participants were recruited and enrolled from HIV clinics at the five health
- 80 facilities. In this sub-study, we included all AdaPT-R participants. Participants who missed viral
- load measurements during their 1st and 2nd year in the study. AdaPT-R participants that had died
- 82 or withdrew from the study before the extended outcome investigation were excluded.

83 Ethical approvals

- 84 The institutional review boards of the University of California, San Francisco (UCSF IRB No.
- 13–12810) and the Kenya Medical Research Institute (KEMRI SSC No 2838) in Kenya
- approved this study. All participants provided informed consent to participate.

87 Measurement of patient characteristics associated with missed viral load

The sociodemographic, socioeconomic, and clinical characteristics of participants were captured at study enrollment from March 2015-October 2018. Data was entered in Open Data Kit (ODK) and the patient clinical characteristics, collected as part of routine patient care, were entered into an electronic medical record system maintained by the Family AIDs Care and Education

It is made available under a CC-BY 4.0 International license .

Program (FACES). The data from both sources were then synchronized daily to the study database. For this sub-study, sociodemographic variables of interest were abstracted from the study database at study enrollment and included age, gender, educational status, marital status and socioeconomic variables including household size, and occupation, as well as clinical characteristics including WHO stage, baseline CD4, study site, and viral load history.

97 Procedures and Measurement

This study and the participating health facilities followed National ART Guidelines for viral load 98 99 monitoring which recommend that viral load testing be conducted 6- and 12-months post ART initiation and annually thereafter for adults with viral suppression (defined as <1000 copies per 100 mL during the study period).[20] Patients without viral suppression undergo adherence 101 102 counseling and repeat viral load is recommended after three months of good adherence. As part of routine care, patient viral load samples are taken at the facility and then sent to centralized 103 laboratories including the Kenya Medical Research Institute -Center for Disease Control 104 105 (KEMRI-CDC) laboratories at Kisian in Kisumu and the Academic Model Providing Access to Healthcare laboratories (AMPATH) in Eldoret for processing. As part of national standards, all 106 results are uploaded and stored on the National STI and AIDs Control Program (NASCOP) 107 website by the laboratories and results are returned to the health facility. Results are then updated 108 in patient medical records, ideally both in paper files and in the electronic medical system 109 110 (EMR). Patients are then informed of results during their next clinic visit if they are suppressed and notified to return to the clinic for their results if they are not suppressed. To examine viral 111 load missingness and drivers of missingness in this sub-study, a two-step process was employed. 112

113 <u>Step 1</u>: Outcome ascertainment (confirming missingness)

It is made available under a CC-BY 4.0 International license .

The study identified patients who did not have a HIV RNA measurement documented in the 114 study database between 9-15 months post ART initiation and 21-27 months post ART initiation 115 (i.e., windows in which guideline recommended 12- and 24-month HIV RNA measurements are 116 to be obtained). Research assistants then explored clinic records by checking the EMR, the 117 patient paper medical records, and the NASCOP website for any viral load within the established 118 window period. If a viral load measurement was found during the window period, the result and 119 date were documented on the report and entered in the study database; the participant was then 120 removed from the missing viral load report. Those who remained on the missing viral report 121 122 moved to Step 2.

123 <u>Step 2:</u> Ascertainment of reason for missing viral load

This involved investigating the missing viral load measurement further through an "extended 124 investigation" and, if the HIV RNA was confirmed missing, classifying the reason for 125 missingness. This occurred during the same month as step 1 then continued monthly until all 126 127 reviews were completed for a single participant. Reasons for missingness were classified based on reviews of patient records and consultations with facility clinicians through a process which 128 encompassed research assistants conducting a series of review in the following order: 1. In-depth 129 review of the entire patient file; 2. Repeat review of the EMR; 3. Examination of laboratory 130 131 records and logs. 4. Repeat review of the NASCOP website; 5. Review study records (e.g., tracking logs); 6. Consultation with research assistants for participants in their case load; and 7. 132 Review study lost to follow up records. Viral loads found through this extended investigation 133 were documented in the study database and the participant was removed from missingness 134 135 report. Classification of missingness was further informed by patient status during the window period of interest and included death, official or self-transferred to another facility, and non-136

It is made available under a CC-BY 4.0 International license .

transfer (Appendix 1). If a non-transfer, the patient file was reviewed to see if the patient had a
clinic visit during the viral load window period of interest and if they did, clinical factors were
examined to determine if it was a: 1. Clinician decision and 2. Viral load ordered, but sample not
collected. The patient status outcomes and clinical factor outcomes were entered in the study
database.

142 Analysis

143 Missed viral load was defined as no viral load results within 9-15 months (First year of study)

and 21-27months of ART initiation (Second year of study). Descriptive statistics were used to

determine the prevalence of missed viral load and reasons for missing viral load measurements.

146 In our analysis we conducted complete case analyses by excluding missing values.

147 Socioeconomic status (SES) indices were generated using multiple correspondence analysis

148 (MCA) using the following variables: occupation of household head, primary source of drinking

149 water, type of cooking fuel, ownership of household assets and ownership of livestock. The

150 households were categorized into five socioeconomic quintiles classified as poorest, poorer,

151 middle, richer and richest [21], [22]. A generalized linear model, using a Poisson distribution

152 with a log-link function, was used to estimate adjusted risk ratios (RR) to determine the patient-

level characteristics associated with missed viral load in year one and year two [23]. We

identified covariates from the literature review and used them in the bivariate and multivariate

analysis [24], [25], [26].

156

157 **Results**

It is made available under a CC-BY 4.0 International license .

- 158 A total of 1815 participants were enrolled to the Adapt-R study. **Table 1** below describes
- 159 participant characteristics at one and two years of follow-up. Sixty-six percent of study
- 160 participants were females and over half (54.8%) were from urban clinics. No differences in
- 161 background characteristics in the first and second year.

Table 1: Background	l Characteristics		
		Overall for year 1 (N=1754) n (%)	Overall for year 2 (N=1709) n (%)
Gender			
	Female	1165(66.4)	1141(66.8)
	Male	589(33.6)	568(33.2)
Age group (Years)			
	<24	280(15.9)	208(12.1)
	24-34	816(46.5)	794(46.4)
	35-44	402(22.9)	431(25.2)
	>44	256(14.6)	276(16.2)
Household Size			
	1-2	393(22.4)	386(22.6)
	3-4	663(37.9)	648(38.0)
	>5	692(39.5)	669(39.2)
Social Economic Status			
	Poorest	351(20.0)	338(19.7)
	Poorer	351(20.0)	341(19.9)
	Middle	351(20.0)	344(20.1)
	Richer	351(20.0)	344(20.1)

Richest	350(19.9)	342(20.0)
Urban	956(54.5)	937(54.8)
Rural	798(45.5)	772(45.2)
1	1,053(61.3)	1032(61.5)
2	508(29.6)	497(29.6)
3	147(8.6)	138(8.2)
4	10(0.5)	9(0.5)
	Urban Rural 1 2 3	Urban 956(54.5) Rural 798(45.5) 1 1,053(61.3) 2 508(29.6) 3 147(8.6)

Table 2: Cumulative incidence of viral load monitoring among ADAPT-R study participants

Viral load post ART initiation	n (%)	
Year 1 (N=1754)	1269(72.3)	
Year 1 Delay* (N=1754)	274(15.6)	
Year 2 (N=1709)	1179(68.9)	
Year 2 Delay* (N=1709)	121(7.1)	

*Delay indicates participants who missed a viral load measure during the window period but later received the viral load test. The drop off in N was due to deaths, study withdrawal or loss to follow up.


It is made available under a CC-BY 4.0 International license .

163

164 Prevalence of missed viral load

- 165 Prevalence of missing viral load at year one was (428/1754) 24.4% whereas the prevalence of
- missing viral load at year two was (502/1709) 29.4%. The cumulative incidence of viral load
- 167 monitoring was 72.3% and 68.9% in year one and two respectively (Table 2) with an additional
- 168 15.6% at year one and 7.1% at year two having delayed viral loads measured.

169 Figure 1. Reasons for Missing Viral Load Measurements at Year 1



170

At year one, the most common reason for missed viral load was due to missing all appointments, and thus being lost to follow up, during the VL window period (N= 209 (51.5%). However, of the 406 patients who were alive and missed VL monitoring measurements, 149 (36.7%) missed viral load monitoring as a result of mis-interpretation of routine viral load monitoring guidelines with clinicians ordering VL 12 months from the last VL done as opposed to 12 months from ART initiation., An additional 42 (10.3%) patients had unknown reason for missed VL and 6


It is made available under a CC-BY 4.0 International license .

177 (1.5%) patients had viral load ordered but there was no evidence the samples were collected.

178 (Figure 1)

179

180 Figure 1. Reasons for Missing Viral Load Measurements at Year 2



181

Similarly, at year two, of the 475 patients who were alive and did not have a VL measured, the most common reason was missed appointments (N=275 (57.8%)), with 153 (32.2%) patients missing their viral load measurements because of misinterpretation of the guideline timing, 41 (8.6%) with no known documented reason, and 6 (1.3%) had their viral loads requested by the clinicians but there was no evidence the samples were ever collected.(**Figure 2**)

187

Table 3. Multivariate analysis of patient characteristics associated with missed viral load in Year1

Total	Missed VL	Have VL	Unadjusted	Adjusted RR	P-value
 N =					

It is made available under a CC-BY 4.0 International license .

	1754(%)	N=485(%)	N=1269(%)	RR (95%CI)	(95%CI)	
Gender						
Female	1165(66.4)	321(66.2)	844(66.5)	0.98(0.84-1.16)	0.86(0.73-1.01)	0.075
Male	589(33.6)	164(33.8)	425(33.5)	Ref		
Age group (Years)						
<24	280(15.9)	109(22.4)	171(13.4)	2.21(1.63-2.99)*	2.27(1.663.12)*	<0.00]
24-34	816(46.5)	239(49.2)	577(45.4)	1.66(1.25-2.21)*	1.70(1.272.28)*	<0.00
35-44	402(22.9)	92(18.9)	310(24.4)	1.30(0.94-1.79)	1.26 (0.91-1.75)	0.15
>44	256(14.6)	45(9.2)	211(16.6)	Ref		
Household Size						
1-2	393(22.4)	114(23.6)	279(22.0)	Ref		
3-4	663(37.9)	186(38.5)	477(37.6)	0.96(0.79-1.17)	0.99(0.81-1.20)	0.933
>5	692(39.5)	182(37.7)	510(40.2)	0.90(0.74-1.10)	1.03(0.84-1.27)	0.719
SES						
Poorest	351(20.0)	80(16.4)	271(21.3)	Ref		
Poorer	351(20.0)	93(19.1)	258(20.3)	1.16(0.89-1.50)	1.16(0.89-1.52)	0.257
Middle	351(20.0)	108(22.2)	115(23.7)	1.35(1.05-1.73)*	1.30(1.01-1.69)*	0.047
Richer	351(20.0)	115(23.7)	236(18.6)	1.43(1.12-1.83)*	1.51(1.14-1.99)*	0.003
Richest	350(19.9)	89(18.3)	261(20.5)	1.11(0.85-1.45)	1.19(0.87-1.63)	0.263

medRxiv preprint doi: https://doi.org/10.1101/2024.11.22.24317791; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Clinic Urban 956(54.5) Ref 235(48.4) 563(44.3) 1.22(1.02-1.46)* 0.029 Rural 798(45.5) 250(51.5) 706(55.6) 1.12(0.96-1.31) **WHO Stage** 285(60.6) 1 1053(61.3) 768(61.5) Ref 1.09(0.92-1.30) 2 508(29.6) 0.306 137(29.1) 371(29.7) 0.99(0.83 - 1.18)3 147(8.6) 46(9.7)101(8.0) 1.15(0.89-1.14) 1.22(0.94-1.59) 0.117 4 10(0.5) 2(0.4)8(0.6) 0.73(0.21-2.56) 0.76(0.21-2.72)0.681 *significant

RR- risk ratio

SES-Social Economic Status

188

	Total N = 1709(%)	Missed VL N=520(%)	Have VL N=1189(%)	Unadjusted RR (95%CI)	Adjusted RR (95%CI)	P-value
Gender						
Female	1141(66.8)	343(65.9)	798(67.1)	0.98(0.84-1.16)	0.86(0.73-1.01)	0.059
Male	568(33.2)	177(34.1)	391(32.8)	Ref		
Age group (Years)						
<24	208(12.1)	91(17.5)	117(9.8)	1.85(1.42-2.41)*	1.69(1.28-1.22)*	<0.001*
24-34	794(46.4)	253(48.6)	541(45.5)	1.35(1.06-1.71)*	1.27(0.99-1.63)	0.059
35-44	431(25.2)	111(21.3)	320(26.9)	1.09(0.83-1.42)	1.01(0.75-1.33)	0.997

Table 4. Multivariate analysis of patient characteristics associated with missed viral load in year 2

pr	medRxiv preprint doi: https://doi.org/10.1101/2024.11.22.24317791; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.									
	It is made available under a CC-BY 4.0 International license .									
	>44	276(16.1)	65(12.5)	211(17.7)	Ref					
House	ehold Size									
	1-2	386(22.6)	136(26.3)	250(21.0)	Ref					
	3-4	648(38.0)	207(40.1)	441(37.1)	0.90(0.76-1.08)	0.92(0.77-1.10)	0.381			
	>5	669(39.2)	173(33.5)	496(41.7)	0.73(0.60-0.88)	0.82(0.68-1.01)	0.061			
SES										
	Poorest	338(19.7)	84(16.1)	254(21.3)	Ref					
	Poorer	341(19.9)	95(18.2)	246(20.6)	1.12(0.87-1.44)	1.08(0.80-1.40)	0.566			
	Middle	344(20.1)	101(19.4)	243(20.4)	1.18(0.92-1.51)	1.11(0.85-1.44)	0.429			
	Richer	344(20.1)	131(25.1)	213(17.9)	1.53(1.21-1.92)*	1.47(1.03-1.91)*	0.004*			
	Richest	342(20.0)	109(20.9)	233(19.6)	1.28(1.01-1.63)*	1.17(0.87-1.57)	0.287			
Clinic	2									
	Urban	937(54.8)	288(55.3)	649(54.5)	Ref					
	Rural	772(45.2)	232(44.6)	540(45.4)	0.97(0.84-1.12)	1.10(0.92-1.57)	0.264			
WHC	Stage									
	1	1032(61.5)	325(64.1)	707(60.4)	Ref					
	2	497(29.6)	131(25.8)	366(31.3)	0.83(0.70-0.99)	0.88(0.74-1.05)	0.185			
	3	138(8.2)	45(8.8)	93(7.9)	1.03(0.80-1.33)	1.06(0.82-1.37)	0.649			
	4	9(0.5)	6(1.2)	3(0.3)	2.11(1.32-3.38) *	2.39(1.52-3.73) *	<0.001*			

*significant

SES-Social Economic Status

It is made available under a CC-BY 4.0 International license .

189	Multivariate analysis of patient characteristics associated with missed viral load in year 1 and
190	year 2 reveals that younger participants age < 24 years (Year 1 aRR=2.27;95%CI 1.66-3.12;
191	p<0.001, Year 2 aRR= 1.69; 95%CI 1.28-1.22 p<0.001) had a higher risk of missed viral load as
192	compared to those whose age group is > 44 years. Participants whose Socio-Economic Status
193	(SES) were richer (Year 1 aRR=1.51;95%CI 1.14-1.99; p=0.003 and Year 2 aRR= 1.47 95%CI
194	(1.03-1.91, p=0.004) also had a higher risk of missed viral load as compared to those with
195	poorest SES. Additionally, participants from rural clinics in year 1 (aRR=1.22;95%CI 1.02-1.46;
196	p=0.029) had a higher risk of missed viral load as compared to those whose clinics were urban
197	(Table 3 and Table 4), whereas participants in Year 2 categorized as WHO stage 4 had a higher
198	risk of missed viral load compared to participants in WHO stage 1(aRR=2.39; 95%CI 1.52-3.73,
199	P<0.001). Stratified analysis comparing patient characteristics by rural vs urban did not change
200	associations with missed viral load in year 1 and 2 respectively.
201	Additional findings from the research team's perspective revealed that some clinicians
202	deliberately avoiding conducting viral load measurements from patients suspected to be viremic.
203	These were patients who reported missing doses of ART or had tendencies of missing their clinic

appointments. However, this practice was not documented in the patients file but reported by

some clinicians when contacted by the research staff during the extended outcome investigation.

206 **Discussion**

An effective viral load monitoring system is critical to early intervention and prevention of poor health outcomes as a result of viremia for PWH. Poor coverage of clinical monitoring systems impedes the ability of HIV programs and country health officials to determine population outcomes. This study showed that about a third of study participants eligible and due for viral load measurement after initiating treatment were missing their viral load at key monitoring timepoints.

It is made available under a CC-BY 4.0 International license .

These findings are similar a study conducted in South Africa that showed 32% and 26% of the 212 participants did not get a viral load test in the first and second years after ART start [27], [28]. 213 Although WHO recommendation for viral testing led to rapid scale up of viral load monitoring 214 among PWH on treatment, these findings suggest health system issues resulting in less-than-ideal 215 viral load monitoring. Over the past five years there has been considerable improvement in viral 216 217 load monitoring; however, gaps in viral load monitoring of patients still persist [30]. HIV treatment success is defined by early diagnosis, prompt ART initiation and viral suppression [31]. With over 218 a third of the patients missing routine VL measurements, VL monitoring is incomplete, leading to 219 220 undetected cases of failure, resistance, and risk of HIV transmission; subsequently undermining attainment of the UNAIDs 95-95-95 goals [10]. Thus, it is essential to understand why viral load 221 monitoring is incomplete so the gaps can be addressed. 222

This study showed that patient engagement in care plays an important role in the missingness of 223 224 viral loads, with approximately 54.7% of patients missing their viral load because they were lost to follow up. Patients who were lost to follow up had unknown whereabouts and potentially 225 could be out of HIV care, may have self-transferred to another clinic without documentation, or 226 died without the clinic's knowledge. Attrition in care engagement leads to underestimation or 227 overestimation of the progress of HIV care and treatment programs. Participant tracing, social 228 support, and reminder systems may improve retention and lead to more complete viral load 229 monitoring outcomes [16]. Some studies using SMS to enhance HIV care and treatment cascade, 230 by engaging both patients and clinicians for reminders about testing, viral load result 231 232 notification, and patient tracing have proven to be effective [32], [33]. Manpower needs are critical in HIV clinics to follow up patients out of care for care engagement and viral load 233 monitoring [34]. 234

It is made available under a CC-BY 4.0 International license .

Our findings also revealed that patient's missed viral load monitoring due to clinical factors. At 235 both 12 and 24 months after ART initiation, over one third of the patients who were in care 236 missed viral load monitoring measurements because of misinterpretation of the guidelines and 237 failure to ensure patients sent for viral load tests in the laboratory followed through. Although the 238 guidelines indicate viral load monitoring for adults is done at 6, 12, and 24 months after ART 239 240 initiation [35], clinicians commonly interpreted the guidelines as recommending viral loads at 6 months, then 12 months from the last viral load done (e.g. 18 months) and 30 months. The study 241 team struggled to get concurrence on our interpretation of the guidelines with some clinical and 242 program teams during the study period. This demonstrated a gap in understanding of the 243 guidelines translating to incomplete VL monitoring as required. Providers need to know when 244 treatment isn't working, and timely viral load measurement provides that knowledge. This is 245 especially important during the first year on antiretroviral therapy (ART), as most treatment 246 failures occur during this period [36], [37], which is why the 6 and 12-month viral load tests are 247 recommended. It is also motivating for patients to know if their treatment is working to stay on 248 track or to figure out what action is needed. Viral suppression allows patients living with HIV to 249 stay health and to prevent onward HIV transmission. To mitigate these clinical challenges, 250 251 capacity building through training, strong clinical guidance and support supervision by program managers are pivotal components of compliant guideline implementation [38], [39]. 252

We observed that patients living with HIV with a WHO clinical stage 4, those in rural health facilities, younger patients <24 years and those with a higher SES had a higher risk of missing viral load tests. The advance clinical stage results are consistent with findings from a study conducted in Myanmar that examined viral load testing uptake and implementation challenges; the study demonstrated that patients with WHO clinic stage 4 had significantly higher rates of

not being tested for viral load [40]. Perhaps, tracing these patients in addition to those who are 258 259 loss to follow up can reduce the missed opportunity for viral load monitoring and investigating more on patients with advanced HIV. Younger patients <24 years were more likely to miss viral 260 load measurements compared to those above 44 years. This was similar to findings from a study 261 conducted in Gomba, Uganda looking at non uptake of VL that reported people below 25 years 262 263 of age to be less likely to have a VL test [27]. Perhaps younger people are more mobile and likely to be out of care hence missing out on routine viral load monitoring [41]. Patients 264 receiving HIV care and treatment in more rural health facilities such as Migori and Rongo 265 266 counties had a higher risk of missing viral load monitoring measurements compared to those in urban facilities in Kisumu County. It has been shown that the testing rates in urban and 267 developed health facilities are higher compared to rural areas [42]. These discrepancies are due 268 269 to lack of testing equipment, poor access to health facilities, differences in the level of training of the health care workers, and weak transport and storage systems [26], [42], [43]. Low 270 socioeconomic status has extensively been demonstrated to be associated with poor health 271 outcomes such as increased morbidity and mortality, lack of adherence to clinic attendance and 272 treatment [44], [45], [46], [47]. Contrary to these finding, our study showed that those who were 273 richer/socioeconomically advantaged were at a higher risk of missing viral load monitoring 274 measurements compared to the poorest. A possible explanation could be that they felt healthy 275 and disregarded the viral load tests or they could possibly be among those who were disengaged 276 277 in care at the time for viral load test or self-transferred to other facilities. Further investigations are needed to obtain an in depth understanding of this finding. 278

279 Strengths and limitations

It is made available under a CC-BY 4.0 International license .

The extended outcome investigation approach is a good way to complete viral load outcomes at 280 various clinics. Often, we do not routinely explore reasons for missed viral load measurements. 281 This study not only examined the occurrence of missed viral loads but also explored underlying 282 causes. The study obtained routinely collected data from the facilities thus demonstrating real 283 world practice. The study sites' location provided a comparison of the urban and rural facilities in 284 Western Kenya, yet the finding may not be generalizable to other regions of Kenya. We were not 285 able to establish other factors that could have led to missed viral load-like reagent stock outs, 286 machine breakdown and impact of health care worker strikes on HIV care and treatment. 287 288 Conducting qualitative interviews and facility assessments would have complemented our results. We had information on participants who had transferred to other health facilities but had limited 289 outcome data. Strengthening facility linkage across clinics would ensure continuity of care and 290 291 documentation of patient outcomes. Additionally, clinicians avoided viral load measurements among patients suspected to be viremic. Given that this practice is not documented, we did not 292 obtain data on the estimates of patients who did not receive VL monitoring due to suspected 293 viremia by the clinicians. 294

295

296

297 **Conclusions**

Missed routine viral load monitoring among newly initiating PWH in Kenya remains high. Loss to follow-up is the major source of missing information and could alter overall suppression estimates substantially. Sustainable approaches to keep people living with HIV engaged and strengthening providers alignment with national guidelines can help public health systems make the most of viral load monitoring technology among patients living with HIV.

It is made available under a CC-BY 4.0 International license .

303 Competing interests

304 All authors report no conflict of interest.

305

306 Authors' contributions

HAF and EG conceptualized and designed the study. HAF, SI, EN, and JK were responsible for
data collection. EN performed data analysis and interpretation. HAF drafted the initial manuscript.
All authors critically reviewed the manuscript, contributed to revisions, and approved the final
version for submission.

311

312 Acknowledgements

We would like to thank all the ADAPT-1 study staff for their invaluable contributions to this manuscript. Special thanks to the Research Assistants who were key in the investigation process and all the study participants.

316

317 Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

320

321

- 322
- 323

324

It is made available under a CC-BY 4.0 International license .

326 Appendix A: Extended outcome investigation form (EOIC).

Anner	dix B28 ADAPT44	Exte	nded (Dutcor	ne Investigation and Classifica	tion form	
Appendix B28_ADAPT4A Extended Outcome Investigation and Classification form Study ID:							
Anniversary	Date:		_	Viral I	Load (VL) window:		
Date of Enro	DD-MMM-YY Iment: DD-MMM-YYY			Start (date: DD-MMM-YYYY	End date:	DD-MMM-YYYY
			Section	n A: Pa	itient status during VL window	1	
Died before	or during VL window	?		⊳↓	Yes: Death date DD-MMM- Fill ADAPT OA form and discontin		Move to Section D
Withdrew fro or during VL	om ADAPT study befo window?	ore		⊳↓	Yes: Withdrawal date DD-1 Fill ADAPT withdrawal form	MMM-YYYY	Move to Section D
	out of ADAPT clinics ring the VL window?		□ No Move Sectio	to	☑ Yes: Transfer-out date DD- Fill discontinuation form, if neede	MMM-YYYY d A	– Nove to Section B
			5	Sectio	n B: Transfer-out patient		
Type of trans	sfer out:	🗆 s	elf Tra	nsfer	Official Transfer		
	\square No \rightarrow		□ Staff is certain patient is/was not in care during window □ Staff has no knowledge of patient whereabouts Move to Section D				
Can you confirm the patient attended a new clinic?	□ Yes ↓ Attempt to get VL data. If able, enter data in ODK. <u>STOP</u> <u>HERE</u> If unable to get VL information within the window period→	 New clinic refused to provide any additional information on the patient New clinic has not taken VL because patient not on treatment, or recently started treatment, or patient enrolled as new at the clinic New clinic has some evidence patient is in care but cannot obtain VL No VL result available, reason unknown New clinic certain patient is/was not in care in the VL window New clinic obtained VL outside window period(VL date and result) Move to Section D 					
					n C: Non-transfer patient	,	
Did patient	□ No →	lf ⊡ s	<i>patien</i> taff ha	<i>t trans</i> ve son	patient is/was not in care during ferred filled Section B. If patient ne evidence patient is in care, bu owledge of patient whereabout	died, fill Sectio ut cannot obtai	
Indee a visit □ Clinician refused to order because patient not on treatment or recently rest Indee a visit □ Clinician refused to order because patient not on treatment or recently rest Indee a visit □ Clinician refused to order because ADAPT window did not match time point VL □ Yes → □ Clinician did not order, reason unknown □ Clinician ordered, but no evidence VL ever collected □ No VL ordered, but known to staff to be off medication completely						or recently restarted atch time points for	
		Se	ction D): Data	sources(select multiple choice	s)	
Data sources	Clinic patient file Clinic Lab Log New clinic staff (transfer patients only) Clinic staff (e.g. SSD, clinical team, Lab technicians) A4A records (e.g. patient files, logs, diaries) IP-Nav knowledge E-navigator knowledge A4A LTFU investigator CM team EVL/ eid website						

327

- "Global HIV & AIDS statistics 2019 fact sheet." Accessed: Feb. 20, 2020. [Online].
 Available: https://www.unaids.org/en/resources/fact-sheet
- J. Kadima *et al.*, "Adoption of routine virologic testing and predictors of virologic failure
 among HIV-infected children on antiretroviral treatment in western Kenya," *PLoS One*, vol.
 12 no. 11 New 2018, doi: 10.1271/journal.neme.0200242
- 334
 13, no. 11, Nov. 2018, doi: 10.1371/journal.pone.0200242.
- C. Laxmeshwar *et al.*, "Routine viral load monitoring and enhanced adherence counselling
 at a public ART centre in Mumbai, India," *PLoS One*, vol. 15, no. 5, p. e0232576, May
 2020, doi: 10.1371/journal.pone.0232576.
- M. S. Saag *et al.*, "HIV viral load markers in clinical practice," *Nat Med*, vol. 2, no. 6, pp. 625–629, Jun. 1996, doi: 10.1038/nm0696-625.
- S.-P. Eholié, F. E. Aoussi, I. S. Ouattara, E. Bissagnéné, and X. Anglaret, "HIV treatment and care in resource-constrained environments: challenges for the next decade," *J Int AIDS Soc*, vol. 15, no. 2, p. 17334, Aug. 2012, doi: 10.7448/IAS.15.2.17334.
- S. Lecher, "Progress with Scale-Up of HIV Viral Load Monitoring Seven Sub-Saharan
 African Countries, January 2015–June 2016," *MMWR Morb Mortal Wkly Rep*, vol. 65,
 2016, doi: 10.15585/mmwr.mm6547a2.
- N. S. Mark *et al.*, "Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in Uganda," *AIDS Res Treat*, vol. 2019, p. 9271450, Dec. 2019, doi: 10.1155/2019/9271450.
- [8] P. D. Ehrenkranz *et al.*, "The missed potential of CD4 and viral load testing to improve clinical outcomes for people living with HIV in lower-resource settings," *PLOS Medicine*, vol. 16, no. 5, p. e1002820, May 2019, doi: 10.1371/journal.pmed.1002820.
- R. V. Barnabas, P. Revill, N. Tan, and A. Phillips, "Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review," *J Int AIDS Soc*, vol. 20 Suppl 7, 2017, doi: 10.1002/jia2.25006.
- B. Nyagadza *et al.*, "Scaling up HIV viral load monitoring in Manicaland, Zimbabwe:
 challenges and opportunities from the field," *Public Health Action*, vol. 9, no. 4, pp. 177– 181, Dec. 2019, doi: 10.5588/pha.19.0024.
- [11] A. E. D. M. S. Housny, M. M. Azab, M. M. M. El Bahnasawy, A. Hassan, and A. R.
 Mohamed, "MONITORING THE VIRAL LOAD IN HIV PATIENTS UNDER ANTIRETROVIRAL THERAPY (ART)," *J Egypt Soc Parasitol*, vol. 46, no. 2, pp. 347–352,
 Aug. 2016.
- A. Phillips *et al.*, "Sustainable HIV Treatment in Africa through Viral Load-Informed
 Differentiated Care," *Nature*, vol. 528, no. 7580, pp. S68–S76, Dec. 2015, doi:
 10.1038/nature16046.
- 365 [13] M. Mwau *et al.*, "Scale-up of Kenya's national HIV viral load program: Findings and
 366 lessons learned," *PLOS ONE*, vol. 13, no. 1, p. e0190659, Jan. 2018, doi:
 367 10.1371/journal.pone.0190659.
- 368 [14] "WHO-HIV-2017.22-eng.pdf."
- [15] M. Mwau *et al.*, "Scale-up of Kenya's national HIV viral load program: Findings and lessons learned," *PLOS ONE*, vol. 13, no. 1, p. e0190659, Jan. 2018, doi: 10.1371/journal.pone.0190659.
- [16] E. H. Geng *et al.*, "Adaptive Strategies for Retention in Care among Persons Living with
- 373 HIV," *NEJM Evidence*, vol. 2, no. 4, p. EVIDoa2200076, Mar. 2023, doi:
- 374 10.1056/EVIDoa2200076.

[17] "hiv prevalence in kisumu county - Google Search." Accessed: May 27, 2021. [Online]. 375 Available: 376 https://www.google.com/search?g=hiv+prevalence+in+kisumu+county&rlz=1C5CHFA en 377 378 KE764KE773&og=hiv+prevalence+in+kisumu+county&ags=chrome..69i57.1261j0j15&so urceid=chrome&ie=UTF-8 379 [18] "New Health Worker Cadre Expands HIV Services in Migori County, Kenya | IntraHealth." 380 Accessed: May 27, 2021. [Online]. Available: https://www.intrahealth.org/news/new-381 health-worker-cadre-expands-hiv-services-migori-county-kenya 382 [19] "Kenya's National HIV Survey Shows Progress Towards Control of the Epidemic. Nairobi, 383 20th February 2020 - MINISTRY OF HEALTH." Accessed: May 27, 2021. [Online]. 384 385 Available: https://www.health.go.ke/kenyas-national-hiv-survey-shows-progress-towardscontrol-of-the-epidemic-nairobi-20th-february-2020/ 386 [20] "ICAP COUIN Final-Kenva-VL-OIC Change-Package-1.pdf." Accessed: Mar. 05, 2020. 387 [Online]. Available: https://cquin.icap.columbia.edu/wp-388 content/uploads/2018/10/ICAP CQUIN Final-Kenya-VL-QIC Change-Package-1.pdf 389 [21] N. Amek et al., "Using health and demographic surveillance system (HDSS) data to 390 391 analyze geographical distribution of socio-economic status; an experience from KEMRI/CDC HDSS," Acta Trop, vol. 144, pp. 24-30, Apr. 2015, doi: 392 10.1016/j.actatropica.2015.01.006. 393 [22] K. Su-Myat, J. de TIBEIRO, and P. Kumar, "An Integrated Approach to Regression 394 Analysis in Multiple Correspondence Analysis and Copula Based Models," Journal of 395 Statistics Applications & Probability, vol. 1, pp. 67–87, Jul. 2012, doi: 396 397 10.12785/jsap/010201. [23] P. Cummings, "Methods for Estimating Adjusted Risk Ratios," The Stata Journal, vol. 9, 398 no. 2, pp. 175–196, Aug. 2009, doi: 10.1177/1536867X0900900201. 399 400 [24] S. Swannet et al., "Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs," Int Health, vol. 9, no. 4, pp. 206-214, 401 Jul. 2017, doi: 10.1093/inthealth/ihx021. 402 [25] B. C. Sninsky, S. Y. Nakada, and K. L. Penniston, "Does socioeconomic status, age, or 403 gender influence appointment attendance and completion of 24-hour urine collections?," 404 Urology, vol. 85, no. 3, pp. 568–573, Mar. 2015, doi: 10.1016/j.urology.2014.10.043. 405 [26] F. Vogt et al., "Access to CD4 Testing for Rural HIV Patients: Findings from a Cohort 406 Study in Zimbabwe," PLoS One, vol. 10, no. 6, p. e0129166, 2015, doi: 407 10.1371/journal.pone.0129166. 408 [27] R. Nakalega et al., "Non-uptake of viral load testing among people receiving HIV treatment 409 in Gomba district, rural Uganda," BMC Infect Dis, vol. 20, no. 1, p. 727, Oct. 2020, doi: 410 10.1186/s12879-020-05461-1. 411 [28] H. Sunpath et al., "Targeting the third '90': introducing the viral load champion," Public 412 413 *Health Action*, vol. 8, no. 4, pp. 225–231, Dec. 2018, doi: 10.5588/pha.18.0063. [29] P. Ondoa et al., "Access to HIV Viral Load Testing and Antiretroviral Therapy Switch 414 Practices: A Multicountry Prospective Cohort Study in Sub-Saharan Africa," AIDS 415 416 Research and Human Retroviruses, vol. 36, no. 11, pp. 918–926, Nov. 2020, doi: 10.1089/aid.2020.0049. 417 [30] S. Swannet et al., "Journey towards universal viral load monitoring in Maputo, 418 419 Mozambique: many gaps, but encouraging signs," International Health, vol. 9, no. 4, pp. 420 206–214, Jul. 2017, doi: 10.1093/inthealth/ihx021.

- [31] A. E. D. M. S. Housny, M. M. Azab, M. M. M. El Bahnasawy, A. Hassan, and A. R. 421 Mohamed, "MONITORING THE VIRAL LOAD IN HIV PATIENTS UNDER ANTI-422 RETROVIRAL THERAPY (ART)," J Egypt Soc Parasitol, vol. 46, no. 2, pp. 347–352, 423 424 Aug. 2016. [32] E. King *et al.*, "Mobile Text Messaging to Improve Medication Adherence and Viral Load 425 in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A 426 Repeated Measures Study," J Med Internet Res, vol. 19, no. 6, p. e190, Jun. 2017, doi: 427 10.2196/jmir.6631. 428 [33] E. Venables et al., "Patient and health-care worker experiences of an HIV viral load 429 intervention using SMS: A qualitative study," PLOS ONE, vol. 14, no. 4, p. e0215236, Apr. 430 431 2019, doi: 10.1371/journal.pone.0215236. [34] B. Burmen, N. Owuor, and P. Mitei, "An assessment of staffing needs at a HIV clinic in a 432 Western Kenva using the WHO workload indicators of staffing need WISN, 2011," Hum 433 Resour Health, vol. 15, p. 9, Jan. 2017, doi: 10.1186/s12960-017-0186-3. 434 [35] "Kenva-ARV-Guidelines-2022-Final-1.pdf." 435 [36] A. Reepalu et al., "Drug Resistance in HIV-Positive Adults During the Initial Year of 436 437 Antiretroviral Treatment at Ethiopian Health Centers," Open Forum Infect Dis, vol. 8, no. 4, p. ofab106, Mar. 2021, doi: 10.1093/ofid/ofab106. 438 [37] D. Haile, A. Takele, K. Gashaw, H. Demelash, and D. Nigatu, "Predictors of Treatment 439
- Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South
 Eastern Ethiopia," *PLoS One*, vol. 11, no. 10, p. e0164299, Oct. 2016, doi:
 10.1371/journal.pone.0164299.
- [38] S. Carmona, T. Peter, and L. Berrie, "HIV viral load scale-up: multiple interventions to
 meet the HIV treatment cascade," *Curr Opin HIV AIDS*, vol. 12, no. 2, pp. 157–164, 2017,
 doi: 10.1097/COH.0000000000352.
- [39] J. Gibb, J. Chitsulo, C. Chipungu, M. Chivwara, A. Schooley, and R. M. Hoffman,
 "Supporting Quality Data Systems: Lessons Learned from Early Implementation of Routine
 Viral Load Monitoring at a Large Clinic in Lilongwe, Malawi," *Journal of clinical research in HIV AIDS and prevention*, vol. 3, no. 1, 2017, doi: 10.14302/issn.2324-7339.jcrhap-171468.
- [40] K. K. Thinn *et al.*, "Uptake of routine viral load testing among people living with HIV and
 its implementation challenges in Yangon region of Myanmar: a mixed-methods study," *BMJ Open*, vol. 9, no. 12, Dec. 2019, doi: 10.1136/bmjopen-2019-032678.
- 454 [41] "Mobility among youth in Rakai, Uganda: Trends, characteristics, and associations with
 455 behavioural risk factors for HIV," *Global Public Health*, Accessed: Aug. 09, 2022.
- [Online]. Available: http://www.tandfonline.com/doi/abs/10.1080/17441692.2015.1074715
 [42] T. Roberts, J. Cohn, K. Bonner, and S. Hargreaves, "Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges," *Clinical Infectious Diseases*, vol. 62, no. 8, pp. 1043–1048, Apr. 2016, doi:
- 460 10.1093/cid/ciw001.
- [43] W. S. Stevens and T. M. Marshall, "Challenges in implenting HIV load testing in South
 Africa," *The Journal of Infectious Diseases*, vol. 201, no. Supplement_1, pp. S78–S84, Apr.
 2010, doi: 10.1086/650383.
- [44] N. C. Arpey, A. H. Gaglioti, and M. E. Rosenbaum, "How Socioeconomic Status Affects
 Patient Perceptions of Health Care: A Qualitative Study," *J Prim Care Community Health*,
 vol. 8, no. 3, pp. 169–175, Jul. 2017, doi: 10.1177/2150131917697439.

- 467 [45] D. J. McMaughan, O. Oloruntoba, and M. L. Smith, "Socioeconomic Status and Access to
- Healthcare: Interrelated Drivers for Healthy Aging," *Frontiers in Public Health*, vol. 8, p.
 231, 2020, doi: 10.3389/fpubh.2020.00231.
- [46] E. Politzer, A. Shmueli, and S. Avni, "The economic burden of health disparities related to socioeconomic status in Israel," *Israel Journal of Health Policy Research*, vol. 8, no. 1, p.
 472 46, May 2019, doi: 10.1186/s13584-019-0306-8.
- 473 [47] E. L. McQuaid and W. Landier, "Cultural Issues in Medication Adherence: Disparities and
- 474 Directions," *J GEN INTERN MED*, vol. 33, no. 2, pp. 200–206, Feb. 2018, doi:
- 475 10.1007/s11606-017-4199-3.
- 476

Figure 1. Reasons for Missing Viral Load Measurements at Year 1




Figure 1_Year 1-VL

Figure 1. Reasons for Missing Viral Load Measurements at Year 2




Figure 2_Year 2-VL